ThromboGenics to remain standalone company, CFO to resign

ThromboGenics today issued a press release stating that it will continue as a standalone company and plans to pursue discussions for a potential partnership for the commercialization of Jetrea in the United States.The release stated separately that Chris Buyse, current chief financial officer and a board member for ThromboGenics, has resigned from his position, effective as of June 30.